Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl 13.9% Cream in Women with Unwanted Facial Hair

This article reports the results of an open-label, multiple-dose study to determine percutaneous absorption and pharmacokinetics of eflornithine following topical treatment with eflornithine HCl 13.9% cream (Vaniqa™). Ten women with excessive facial hair were treated with two 0.5 g single doses of [...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2001-09, Vol.41 (9), p.972-978
Main Authors: Malhotra, Bimal, Noveck, Robert, Behr, Douglas, Palmisano, Maria
Format: Article
Language:English
Subjects:
Administration, Topical
Adolescent
Adult
Area Under Curve
Biological and medical sciences
Eflornithine - administration & dosage
Eflornithine - pharmacokinetics
Eflornithine - therapeutic use
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - pharmacokinetics
Enzyme Inhibitors - therapeutic use
Feces - chemistry
Female
Hair Removal
Hirsutism - drug therapy
Hirsutism - metabolism
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Skin Absorption - physiology
Skin, nail, hair, dermoskeleton
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article reports the results of an open-label, multiple-dose study to determine percutaneous absorption and pharmacokinetics of eflornithine following topical treatment with eflornithine HCl 13.9% cream (Vaniqa™). Ten women with excessive facial hair were treated with two 0.5 g single doses of [C]-labeled eflornithine HCl 13.9% (w/w) cream (periods A and C) separated by twice-daily application of 0.5 g unlabeled eflornithine HCl 13.9% cream for 7 days (period B). Analysis of radioactivity excreted in urine and feces indicated that percutaneous absorption was minimal. Comparison with urinary excretion of eflornithine in period A suggested that most of absorbed eflornithine was excreted in urine without being metabolized. Radioactivity was not detectable in blood or plasma, but eflornithine concentrations were measurable, with peak concentrations of 4.96 ng/ml in period A and 10.44 ng/ml in period C. Eflornithine was eliminated from plasma with a mean terminal half-life of 11 hours (first application) and 8 hours (final application). Trough plasma concentrations reached steady state (4.61–5.50 ng/ml) after 4 days of twice-daily topical treatment, and multiple dosing had no apparent effect on disposition kinetics. The low degree of percutaneous absorption and low systemic exposure to eflornithine offer a favorable clinical safety profile of eflornithine HCl 13.9% cream.
ISSN:0091-2700
1552-4604
DOI:10.1177/00912700122010951